| 摘要 |
<p>#CMT# #/CMT# Yeast cells (I), for prevention or treatment of stomach or intestinal ulcers, are new. #CMT# : #/CMT# Independent claims are included for: (1) a pharmaceutical composition comprising (I) as an active ingredient, at least one active ingredient having gastrointestinal toxicity, optionally in association with a vehicle; and (2) a kit comprising (I) in a primary compartment, and at least one active ingredient having gastrotoxic activity in a secondary compartment. #CMT#ACTIVITY : #/CMT# Antiulcer. #CMT#MECHANISM OF ACTION : #/CMT# None given. #CMT#USE : #/CMT# (I) is useful for prevention or treatment of stomach or intestinal ulcers; and for prevention or treatment of duodenal or gastric ulcers (preferred). The ulcers are induced by: an active ingredient having gastrointestinal toxicity; nonsteroidal antiinflammatory drug; and ibuprofen (all claimed). The ability of (I) to treat ulcer was tested in rats. The result showed that Saccharomyces boulardiiexhibited decreased 64% of the number of ulcers and 74% of the ulcerated surface. #CMT#BIOLOGY : #/CMT# Preparation: No preparation method is given. Preferred Components: (I) are genus Saccharomyces. (I) are Saccharomyces boulardiispecies. (I) are lyophilized. (I) are Saccharomyces, preferably Saccharomyces boulardii. #CMT#ADMINISTRATION : #/CMT# Administration of (I) is 0.5x 10 8>to 100x 10 1>0>colony forming unit/kg/day, in the form of capsules or sachets (claimed). Administration of (I) is oral. #CMT#EXAMPLE : #/CMT# No suitable example given.</p> |
